Discovery of in vivo Chemical Probes (R01) | Apply Online

Opportunity Summary:

The NIH funding opportunity titled "Discovery of in vivo Chemical Probes (R01)" (Funding Opportunity Number PAR-14-279) was a discretionary NIH research grant aimed at supporting projects that advance the discovery and development of chemical probes that work in living systems. The central idea is to fund investigators who can take promising early compounds and push them into more refined, biologically informative tools that can be used in vivo, meaning in animals or other living models where the complexity of real biology can reveal whether a molecule truly engages its target and produces meaningful effects. This program is positioned less as basic screening support and more as an enablement mechanism for teams that are already beyond the earliest discovery stage and are ready to optimize and validate.

A key expectation of the announcement is that applicants already have "starting compounds" in hand, described as validated hits, along with relevant bioassays that can be used to test newly synthesized analogs. In practical terms, this means NIH was looking for proposals where the project is ready to move into iterative medicinal chemistry and experimental validation: designing and synthesizing improved versions of a molecule, testing those compounds in fit-for-purpose assays, and demonstrating that the resulting probe has the properties needed to answer real biological questions in vivo. The emphasis on having validated hits up front signals that this FOA was not primarily intended to fund broad, exploratory high-throughput screening from scratch, but rather the optimization and translation of existing chemical matter into robust probes.

The FOA highlights two main research goals. First, it seeks discovery and development of novel small molecules that can be used to study disease treatment-relevant biology aligned with the missions of participating NIH Institutes. In other words, the chemical probes should not just be chemically interesting; they should be useful for studying pathways, targets, or mechanisms that matter for human health and disease areas NIH supports. Second, it aims to enable the discovery and/or validation of novel biological targets, with the intent of informing deeper studies of disease mechanisms. That target-focused piece is important because a strong in vivo probe can do more than inhibit or activate a protein; it can help confirm whether a proposed target is actually causal in a disease process, clarify where and when a pathway matters, or reveal unexpected biology that changes how a disease is understood.

Across both goals, the announcement explicitly stresses that projects offering new insight into important disease targets and processes would be prioritized. This frames the program as impact-driven: successful applications would typically connect chemical optimization work to a clear plan for in vivo use, show how the probe will answer a specific biological or translational question, and demonstrate why the target or process is important. The ideal end product is a well-characterized in vivo chemical probe that is selective and potent enough to interpret biological outcomes confidently, with accompanying data that strengthens confidence in the target and its relevance to disease.

Administratively, this was an NIH R01 grant mechanism under the broader categories of education, health, and social services, and it was associated with multiple CFDA numbers spanning a wide range of biomedical domains. Those listed areas include research related to deafness and communication disorders (93.173), mental health (93.242), alcohol (93.273), drug abuse and addiction (93.279), cancer detection/diagnosis (93.394), cancer treatment (93.395), arthritis and musculoskeletal/skin diseases (93.846), child health and human development (93.865), aging (93.866), and vision research (93.867). The breadth of these program areas reflects that the chemical probe concept is cross-cutting: the same general approach of making in vivo-capable tool compounds can accelerate research in neuroscience, oncology, immunology, aging biology, and many other fields.

Eligibility was broad and included many types of organizations: public and private institutions of higher education, nonprofits (including 501(c)(3) organizations), small businesses and other for-profit organizations, independent school districts, and various governmental entities (city, county, state, special district, and certain housing authorities). The eligibility language also extended to a wide set of additional applicant types such as historically Black colleges and universities, Hispanic-serving institutions, tribally controlled colleges and universities, Alaska Native and Native Hawaiian-serving institutions, Asian American and Native American Pacific Islander-serving institutions, tribal organizations and governments (including some not federally recognized), faith-based and community-based organizations, regional organizations, U.S. territories or possessions, and even non-U.S. entities (foreign organizations). The FOA did not require cost sharing or matching funds, which can lower barriers for applicants proposing complex chemistry and in vivo biology that already demand substantial resources.

In terms of timing, the opportunity was posted and created on July 11, 2014, with an original and current closing date of September 6, 2017, and it was archived on October 7, 2017. The sponsoring agency was the National Institutes of Health. The announcement provided an NIH grants guide link for full details and listed NIH Office of Extramural Research (OER) webmaster contacts for access or technical issues. Overall, PAR-14-279 can be understood as an NIH effort to push the field toward higher-quality, in vivo-usable chemical tools that both illuminate disease biology and help validate targets with real therapeutic relevance.

Browse more opportunities from the same agency: National Institutes of Health

Browse more opportunities from the same category: Education Health Income Security and Social Services

Next opportunity: Riparian, LWM and Flow Implementation

Previous opportunity: HUMAN EXPLORATION RESEARCH OPPORTUNITIES NASA RESEARCH ANNOUNCEMENT

USGrants.org Applicant Portal:

Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.

Apply for PAR 14 279

 

[Watch] how do funding administrators access proposals?

Applicants also applied for:

Applicants who have applied for this opportunity (PAR 14 279) also looked into and applied for these:

 

Grant application guides and resources

It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!

Apply for Grants

 

 

Premium leads for funding administrators, grant writers, and loan issuers

Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.

If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.

Subscribe to Leads

 

Request more information:

Would you like to learn more about this funding opportunity, similar opportunities to "PAR 14 279", eligibility, application service, and/or application tips? Submit an inquiry below:

Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.